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ABSTRACT: Introduction: Adult muscle fibers are a source
of growth factors, including insulin-like growth factor-1 (IGF-1).
These factors influence neuronal survival, axonal growth, and
maintenance of synaptic connections. Methods: We investi-
gated the components of the IGF system in skeletal muscle
samples obtained from 17 sporadic amyotrophic lateral sclero-
sis patients (sALS) and 29 control subjects (17 with normal
muscle and 12 with denervated muscle unrelated to ALS).
Results: The muscle expression of IGF-1 and IGF-binding pro-
teins 3, 4, and 5 (IGF-BP3, -4, and -5, respectively), assessed
by immunohistochemistry, was differently decreased in sALS
compared with both control groups; conversely, IGF-1 receptor
b subunit (IGF-1Rb) was significantly increased. Western blot
analysis confirmed the severe reduction of IGF-1, IGF-BP3, and
-BP5 with the increment of IGF-1Rb in sALS. Conclusion: In
this study we describe the abnormal expression of the IGF-1
system in skeletal muscle of sALS patients that could partici-
pate in motor neuron degeneration and should be taken into
account when developing treatments with IGF-1.
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Amyotrophic lateral sclerosis (ALS) is a fatal neu-
romuscular disorder characterized by motor neu-
ron (MN) degeneration that leads to progressive
skeletal muscle atrophy and paralysis. Most ALS
cases are sporadic, but a small percentage (5–10%)
are familial.
Many hypotheses have been formulated to
explain the pathogenesis of sporadic ALS (sALS),
including autoimmune reactions to calcium chan-
nels on MNs, glutamate-induced excitotoxic injury,
exposure to toxins or latent infections, disorganiza-
tion of intermediate ﬁlaments, and loss of neuro-
trophic support to MNs.
1 The latter hypothesis is
of particular interest, because adult muscle ﬁbers
produce molecules that inﬂuence MN survival,
axonal growth, and maintenance of synaptic con-
nections. Among these trophic factors, insulin-like
growth factor-1 (IGF-1) has a key role; it is involved
in muscle and nerve tissue anabolism and thus
induces muscle hypertrophy and promotes neuro-
nal survival.
2–6 The neurotrophic effect of IGF-1
was the starting point for three clinical trials based
on subcutaneous injections of human recombinant
IGF-1 in ALS patients. Disappointingly, these stud-
ies did not show a signiﬁcant positive effect of IGF-
1 therapy on disease progression or survival in ALS
patients.
7–9 However, the therapeutic role of IGF-1
in ALS is still debated. Indeed, Kaspar and col-
leagues demonstrated that treatment with adeno-
associated virus/IGF-1 retrogradely transported
from muscle to MNs of the spinal cord led to ther-
apeutic beneﬁts in the G93A transgenic mouse
model.
10 This effect was further increased with
associated physical exercise.
11
More recently, Dobrowolny et al. reported that
muscle-restricted expression of IGF-1 isoforms
maintained muscle integrity, stabilized neuromus-
cular junctions, reduced inﬂammation in the spi-
nal cord, enhanced motor neuronal survival, and
delayed the onset and slowed disease progression
in sodium dismutase 1 (SOD1) G93A mice.
12,13
Both these studies reappraised the potential role
of the skeletal muscle and IGF-1 signaling as a tar-
get for treatment in ALS patients. Moreover, a
recent study also showed that overexpression of
IGF-1 in muscle attenuates disease in a mouse
model of spinal and bulbar muscular atrophy.
14
The IGF-1 signaling system is complex and
regulated by many factors.
15,16 The components of
the IGF-1 system include a growth factor, IGF-1,
which is a single-chain polypeptide with a molecu-
lar weight of approximately 7.5 kDa. The IGF-1
receptor (IGF-1R) is a membrane glycoprotein of
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kDa each) containing the ligand-binding site, two
b subunits (90 kDa each) containing the hydro-
phobic transmembrane domain, a short extracellu-
lar region, and a tyrosine kinase domain in its cyto-
plasmic portion.
17 Besides IGF-1R, six IGF-binding
proteins (IGF-BPs) have been identiﬁed. This is a
family of secreted proteins that speciﬁcally bind
IGF-1 with afﬁnities that are equal to or greater
than those of the IGF-1R. In terms of IGF-1 func-
tion, it is now well established that some of the
IGF-BPs, such as -BP2, -BP4, and -BP6, inhibit IGF-
1. BP5 potentiates IGF-1 actions, whereas -BP1 and
-BP3 can inhibit or potentiate IGF-1.
18–22 In addi-
tion, numerous data also demonstrate evidence for
IGF-1–independent actions of IGF-BPs, which are
unexpected.
23,24
The lack of information available on the
expression levels of the IGF-1 system in skeletal
muscle of ALS patients led us to investigate the
expression of IGF-1; IGF-BP3, -BP4, -BP5; and IGF-
1R b subunit (IGF-1Rb) in skeletal muscle speci-
mens and primary muscle cell cultures obtained
from sALS patients.
METHODS
Clinical Data for Patients and Control Subjects. We
enrolled 17 sALS patients recruited from the
Department of Neurology of the IRCCS Istituto
Auxologico Italiano (Milan, Italy). The diagnosis
of sALS was based on a detailed history and physi-
cal examination, supported by electrophysiological
evaluation.
25 Other disease causes were excluded
by appropriate blood tests and neuroimaging.
The sALS group included 15 men and 2
women (mean age 55.2 6 11.5 years), and the
patients were classiﬁed according to the revised
El Escorial criteria
26 in the following groups: deﬁ-
nite ALS (n ¼ 6 patients); probable ALS (n ¼ 8);
and possible ALS (n ¼ 3). Thirteen sALS patients
presented with limb onset and 4 with bulbar
onset. The mean Amyotrophic Lateral Sclerosis
Functional Rating Scale—revised (ALS-FRS-R)
score was 32.8 (69.1), and disease duration
r a n g e df r o m3t o9 6m o n t h s( m e d i a n¼ 11
months). All patients had been taking riluzole
for  6m o n t h s .
The control group included 17 subjects with
normal muscle at histological analysis (healthy con-
trols, HCs), divided into 10 men and 7 women
(mean age 54.6 6 14.6 years), and 12 subjects with
non–ALS-related denervation (pathologic controls,
PCs), divided into 7 men and 5 women (mean age
54.1 6 12.1 years). The PC patients included the
following: chronic inﬂammatory demyelinating
polyneuropathy (n ¼ 6); spondylogenic radiculopa-
thy (n ¼ 2); and multifocal motor neuropathy
(n ¼ 4).
The nutritional status, evaluated by body mass
index (BMI ¼ weight/height
2) and serum nutri-
tional parameters (such as total protein, pre-
albumin, and transferrin), was similar in sALS
patients and controls (P > 0.05). Subjects with dia-
betes mellitus were excluded from the study. Open
biopsy was performed in the biceps muscle in all
subjects.
This investigation was approved by the local
ethics committee, and patients signed an informed
consent document consistent with institutional
guidelines.
Histochemical and Immunofluorescence Analyses.
Specimens were frozen in isopentane–liquid nitro-
gen and stored in liquid nitrogen until use. Histo-
logical, histochemical, and immunoﬂourescence
(IF) analyses were carried out on 8-lm-thick frozen
cross-sections. Monoclonal antibodies for IGF-1
and IGF-BP3, -BP4, and -BP5 were supplied by
R&D Systems (Minneapolis, Minnesota), and anti-
bodies for IGF-1Rb were from Upstate Biotechnol-
ogy (Lake Placid, New York). For IGF-1 and IGF-
BP3, -BP4, and -BP5 analyses, muscle sections were
ﬁxed in acetone for 1 min at 4 C and blocked with
normal goat serum in phosphate-buffered saline
(PBS). For IGF-1Rb analysis, tissues were ﬁxed with
4% paraformaldehyde for 15 min at room temper-
ature and permeabilized with 0.01% Triton/PBS
for 5 min at room temperature. Sections were
incubated at 4 C overnight with the primary anti-
bodies and then incubated with secondary antibod-
ies. Secondary biotinylated anti-mouse antibodies
were applied for 30 min (1:100; Amersham Life
Sciences), followed by streptavidin–ﬂuorescein for
30 min (1:100; Amersham). In the case of IGF-
1Rb, secondary Cy2-conjugated goat anti-mouse
IgGs were applied for 1 h (1:200; Jackson Immu-
noResearch, Inc., West Grove, Pennsylvania). All
incubations were carried out at room temperature
in a wet chamber. As negative controls, primary
antibodies were omitted. Sections were examined
under a Zeiss ﬂuorescence microscope. The stud-
ies were analyzed in a blinded fashion by two dif-
ferent investigators (A.P. and M.M.).
To compare the degree of denervation between
sALS and PC skeletal muscles, we used a denerva-
tion index according to Brooke et al.
27 Brieﬂy, the
index was calculated from the histograms of the
muscle ﬁbers and provided the number of abnor-
mally small ﬁbers in the biopsy (denervated
ﬁbers). The parameter was obtained by multiplying
the number of ﬁbers in the histogram with a diam-
eter between 30 and 40 lm by 1, the number of
ﬁbers with a diameter between 20 and 30 lmb y2 ,
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and the number in the group <10 lm by four.
These products were then added together and di-
vided by the total number of ﬁbers in the histo-
gram to show the result on a proportional basis.
Finally, the resulting number was multiplied by
1000.
Western Immunoblotting Analysis. Samples of fro-
zen muscle were homogenized in ice-cold lysis
buffer [0.05 M Tris-HCl, 0.15 M NaCl, 0.8% Triton
X-100, 0.08% sodium dodecylsulfate (SDS), 10 mM
ethylene-diamine tetraacetic acid, 100 lM sodium
vanadate, 0.8% sodium deoxycholate, 50 mM so-
dium ﬂoride, 5 mM iodoacetic acid] containing
1% protease inhibitor cocktail (Sigma-Aldrich, Mi-
lan, Italy). The homogenate was kept on ice for 30
min, centrifuged at 500 rpm for 10 min at 4 C,
and the resulting supernatant centrifuged at
13,200 rpm for 15 min at 4 C. Protein concentra-
tion was determined with the bicinchoninic acid
(BCA) assay (Pierce, Rockford, Illinois). Blood
contamination was excluded by showing the
absence of albumin—measured with an albumin
immune assay (BN2; Behring, Marburg, Germany).
For investigation of IGF-1, IGF-BP, and IGF-1Rb
expression, equal amounts of protein samples (50 lg)
were resuspended in Laemmli sample buffer and
separated in an 8–16% Tris–HEPES–SDS-polyacryl-
amide gel system (Pierce). The separated proteins
were then transferred from the gel to a nitrocellu-
lose membrane overnight at 4 C. The membrane
was blocked with 5% dry milk in Tris-buffered sa-
line/0.1% Tween 20 for 1 h at room temperature,
and the blot was then incubated overnight at 4 C
with a diluted primary antibody solution of anti–
IGF-1 (1:500), anti–IGF-BP3 (1:500), anti–IGF-BP4
(1:500), anti–IGF-BP5 (1:500) (all from R&D Sys-
tems), or anti–IGF-1Rb (1:1000; Cell Signaling
Technology, Danvers, Massachusetts). The subse-
quent incubation with a secondary antibody conju-
gated with peroxidase was performed at room tem-
perature for 2 h. Immunoreactivity was detected by
working solution (SuperSignal West Pico Substrate;
Pierce) and exposure of the membrane to photo-
graphic ﬁlm at room temperature for the required
time.
Primary Muscle Cell Cultures. Primary adult skele-
tal muscle cell cultures were obtained as previously
described.
28 IGF-1Rb expression was evaluated in
cell cultures from 2 sALS patients and 2 healthy,
age-matched controls. Membrane protein fractions
were obtained by solubilization in ice-cold lysis
buffer for 1 h at 4 C and subsequent centrifuga-
tion for 1 h at 4 C at 100,000   g. Protein quantiﬁ-
cation and WB analysis were then conducted as
described earlier.
Statistical Analysis. Statistical analysis for WB
analysis was performed using Prism statistical
analysis software (GraphPad Software, San Diego,
California). Data are given as mean 6 SD. Differ-
ences between groups were evaluated by analysis of
variance (ANOVA), followed by post hoc Tukey
and Dunnett tests and considered signiﬁcant at
P < 0.05.
RESULTS
Histochemical Analysis of Skeletal Muscle. In all
ALS patients, histopathological examination
showed a typical chronic neurogenic pattern, with
groups of atrophic and angulated ﬁbers associated
with diffuse ﬁber-type grouping. The atrophic
ﬁbers were present in large or small groups and
were of both histochemical ﬁber types. The small,
angulated ﬁbers were intensely stained with oxida-
tive enzymes. Target ﬁbers and central nuclei were
also present. Moreover, we selected PC patients
looking for muscle biopsies with a similar degree
of pathological changes, particularly chronic de-
nervation. The degree of denervation was similar
between ALS and PC patients according to histo-
metrical analysis (Table 1).
IF Analysis of IGF-1 System in Skeletal Muscle. Nor-
mal skeletal muscle ﬁbers (HC) showed speciﬁc
signal for IGF-1, IGF-1Rb, and all three IGF-bind-
ing proteins (BP3, BP4, and BP5). Immunoreactiv-
ity for IGF-1 in HC muscles showed a cytoplasmic
distribution characterized by a ‘‘checkerboard’’
pattern (Fig. 1a): type II muscle ﬁbers had weaker
immunostaining when compared with type I mus-
cle ﬁbers (Fig. 1b). In addition, IGF-1Rb reactivity
showed a spotty distribution on the sarcolemma of
HC muscle ﬁbers (Fig. 2a). All three IGF-BPs dis-
played a cytoplasmic location in the muscle ﬁbers
of HC, but some differences were evident among
them. IGF-BP3 and -BP5 were differently expressed
in these muscles, showing a ﬁber type–related dis-
tribution (Fig. 3a and c). The immunobinding was
uniformly evident inside the muscle ﬁbers for IGF-
BP3, whereas it was speckled and more prominent
in the outer region of cytoplasm for IGF-BP5. IGF-
BP4 had a cytoplasmic expression, more concen-
trated next to the sarcolemma, without a speciﬁc
ﬁber-type distribution (Fig. 3b).
Table 1. Histometrical analysis of denervation index in sALS and
PC skeletal muscle.
sALS (n ¼ 17) PC (n ¼ 12) P
Type 1 fibers
(mean 6 SD)
1025 6 645 1234 6 913 0.48
Type 2A and type 2B
fibers (mean 6 SD)
1139 6 782 1191 6 782 0.87
PC, pathologic control.
202 IGF System in Sporadic ALS Skeletal Muscle MUSCLE & NERVE February 2012In PC tissues, the IGF-1 and its BPs were
expressed (Fig. 1c and 3d–f), but their immu-
noreactivity was slightly weaker when compared
with HC muscles. The distribution pattern did
not differ between the two control groups. On
the contrary, IGF-1Rb immunobinding was
FIGURE 1. Histochemical and IF studies of IGF-1 in skeletal muscle. (a) Immunoreactivity for IGF-1 in HC muscles had a cytoplasmic
distribution characterized by a ‘ ‘checkerboard’ ’ pattern. (b) The 9.4 ATPase reaction in HC muscles showed that type II fibers (þ) had
weaker immunostaining compared with type I fibers (*). (c) Although the muscle fibers were differently immunoreactive for IGF-1,
the checkerboard pattern was still evident in PC muscles. (d) In sALS patients, IGF-1 immunostaining was definitely weak, and
the checkerboard pattern was totally lost (muscle cryosections; bar ¼ 50 lm). IF, immunofluorescence; HC, healthy control; PC,
pathological control. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 2. IF studies of IGF-1-Rb in skeletal muscle. (a) In HC muscles, receptor b had a selective distribution in a spotty pattern on
the sarcolemma. (b, c) In PCs and sALS muscles, IGF-1-Rb immunostaining showed increased reactivity compared with HCs; how-
ever, this was more intense in the muscles of sALS patients (muscle cryosections; bar ¼ 50 lm). IF, immunofluorescence; HC, healthy
control; PC, pathological control. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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(Fig. 2b).
In skeletal muscle of sALS patients the immu-
nostaining of IGF-1 and IGF-BP3, -BP4, and -BP5
(Figs. 1d and 3g–i) was decreased when compared
with the control groups. In particular, the reduc-
tion of expression was more evident for IGF-1 and
IGF-BP3 and -BP5. Interestingly, the ‘‘checker-
board’’ pattern observed for IGF-1 and IGF-BP3
and -BP5 was totally lost. Notably, in sALS patients,
immunostaining showed a remarkable increment
of IGF-1Rb spot reactivity at the level of the sarco-
lemma as compared with both healthy and patho-
logical controls (Fig. 2c).
WB Analysis of IGF-1 System in Skeletal Muscle. WB
analysis of skeletal muscle from HCs showed two
main IGF-1 immunoreactive bands, one of 25–30
kDa corresponding to bound IGF-1, and another
<10 kDa, possibly free IGF-1.
29 The intensity of
both signals was markedly lower in sALS muscle
homogenates compared with those from HC and
PC (Fig. 4a and Table 2). WB analysis of IGF-BP3
expression yielded a main band of 29 kDa and
additional 30–35- and 41-kDa bands, correspond-
ing to putative glycosylated forms (Fig. 4b and
Table 2). WB analysis of IGF-BP5 showed a main
band of 28 kDa and other bands of 30–35, 41, and
>50 kDa (Fig. 4c and Table 2). Immunoreactivity
for both IGF-BP3 and -BP5 was dramatically lower
in all sALS homogenates compared with controls.
No signiﬁcant differences were detected for IGF-
BP4 in the muscle samples from all three groups
(data not shown). The IGF-1Rb signal was observed
as a   95-kDa band that was more intense in sALS
muscle tissues compared with HC and PC tissues
(Fig. 4d and Table 2). To conﬁrm the increased
IGF-1Rb expression observed in sALS, we evaluated
the receptor immunoreactivity in primary adult
skeletal muscle cell cultures from 2 sALS patients
and 2 healthy, age-matched controls. The analysis
of protein-enriched membrane samples showed
that sALS cells expressed more IGF-1Rb than con-
trol cells (Fig. 5: C vs. A and D vs. B), corroborat-
ing evidence of an increment of this growth factor
receptor in sALS skeletal muscles. Analysis of
receptor immunoreactivity in primary adult skeletal
muscle cell cultures of PC was not performed.
DISCUSSION
IGF-1 is a trophic factor for different tissues,
including nervous system and skeletal muscle. In
particular, it is a survival factor for motoneurons,
both in vitro and in vivo.
2,30–32 It is also a potent
myogenic factor that promotes myoblast prolifera-
tion, myogenic differentiation, and myotube hyper-
trophy.
2–6 In this study, in which IF and WB analy-
ses were utilized, some IGF-1 system components,
FIGURE 3. Histochemical and IF studies of IGF-BPs in skeletal muscle. (a–c) In HCs, all three IGF-BPs displayed a cytoplasmic dis-
tribution. In particular, immunoreactivity for both IGF-BP3 (a) and IGF-BP5 (c) showed a ‘ ‘checkerboard’ ’ pattern, in which type II mus-
cle fibers (l, m) (*) showed weak immunostaining compared with type I fibers (l, m)( þ). The signal was uniform inside the muscle
fibers for IGF-BP3 (a), higher next to the muscle fiber surface for IGF-BP4 (b), and scattered for IGF-BP5 (c). In PC tissues, the im-
munoreactivity of the three IGF-BPs (d–f) was slightly weaker as compared with HC tissues, whereas the distribution pattern did not
differ between the two control groups. In skeletal muscle of sALS patients, expression of the investigated BPs (g–i) was significantly
decreased compared with the control groups (muscle cryosections; bar ¼ 50 lm). IF, immunofluorescence; HC, healthy control; PC,
pathologic control. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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(BP3, BP4, and BP5), were less expressed in skele-
tal muscle in sALS patients than in normal and
pathological controls. On the contrary, the muscle
expression of IGF-1Rb was increased in sALS
patients compared with controls. These data might
reﬂect a worrisome inhibition of the action of the
IGF-1 system in skeletal muscles of sALS patients
that could inﬂuence the course of the disease.
Wilczak et al. investigated the components of
the IGF-1 system in spinal cord sections of patients
with ALS.
29 They reported that free IGF-1 concen-
trations were lower in ventral horn homogenates
from ALS patients than in those from controls; in
addition, IGF-1R immunoreactivity was enhanced
in ALS spinal MNs. Indeed, our study disclosed a
similar dysfunction of the IGF-1 system in another
compartment of sALS patients that could play an
important role in both MN degeneration and mus-
cle atrophy. On the other hand, Millino et al.
found that patients with spinal muscular atrophy
FIGURE 4. Representative WB experiment and densitometric analysis (mean 6 SD) of IGF-1 (a), IGF-BP3 (b), IGF-BP5 (c), and
IGF-1Rb (d) expression for HC, sALS, and PC skeletal muscle.
*P < 0.05 vs. HC;
**P < 0.01 vs. HC and PC. WB, Western blot; HC,
healthy control; PC, pathologic control.
Table 2. Densitometric WB analysis of IGF-1, IGF-BP3, IGF-BP5,
and IGF-1Rb in HC, sALS, and PC skeletal muscle.
HC sALS PC
IGF-1
7–10-kDa band 3933 6 3057 399 6 115* 3973 6 1125
30-kDa band 4210 6 542 367 6 101
† 2792 6 564
IGF-BP3
29-kDa band 22,061 6 5030 4291 6 1932* 7490 6 1471
30–35-kDa
band
17,445 6 3080 4177 6 1775
† 6712 6 1687
41-kDa band 15,067 6 2970 2171 6 796
† 7413 6 1858
IGF-BP5
28-kDa band 18,697 6 4998 1742 6 460
† 7146 6 1788
30–35-kDa
band
12,158 6 2548 1613 6 410
† 9404 6 2852
41-kDa band 14,145 6 2759 2207 6 637
† 6968 6 2011
>50-kDa
band
14,593 6 4078 2668 6 539* 9082 6 4232
IGF-1Rb
95-kDa band 4778 6 2078 17,392 6 3822
† 9081 6 4726
Data are presented as mean 6 SD. WB, Western blot; HC, healthy con-
trol; PC, pathologic control.
*P < 0.05 vs. HC.
†P < 0.01 vs. HC and PC.
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mutations of the survival MN gene and characterized
by muscle weakness and atrophy caused by degener-
ation of spinal MNs, showed reduced expression of
the genes involved in the IGF/PI3K/Akt pathway
with an overexpression of the IGF-1R gene.
33
Several hypotheses on the cause of this reduced
activation of the IGF-1 system should be considered.
First, nutrition is one of the main regulators of circu-
lating IGF-1, so low nutrient intake downregulates
IGF-1 gene transcription
34 and reduces serum IGF-1
concentrations. The exquisite sensitivity of circulating
IGF-1 to nutrients, the nycthemeral stability of its con-
centrations, and its relatively short half-life constitute
the basis for its use as a marker of both nutritional sta-
tus and adequacy of nutritional rehabilitation. Maz-
zini et al. reported that, at the onset of medical
attendance, 53% of their ALS patients had a BMI <20
kg/m
2, and 55% had a weight loss of >15% of their
usual weight. These data indicate a high occurrence
of malnutrition in ALS patients that leads to an
impairment of muscle function eventually mediated
by reduced IGF-1 availability.
35 T h i sw a sn o tt h ec a s e
for the patients we studied, because they did not show
any alteration of parameters of nutritional status.
A second hypothesis may be related to the role
of cytokines in ALS. Accumulating evidence from
studies in both cell cultures and ALS animal mod-
els suggests that the pro-inﬂammatory cytokine,
tumor necrosis factor-a (TNF-a), may participate in
the death of MNs, even from the early pathogenic
events of the neurodegenerative process.
36,37 Both
serum TNF-a and its soluble receptors have been
reported to be signiﬁcantly higher in ALS patients
compared with healthy controls.
38 Moreover, TNF-
a impairs skeletal muscle trophism. In this context,
activation of TNF-a signaling via the c-Jun N-termi-
nal kinase can decrease IGF-1 RNA expression and
inhibit IGF-1 signaling by phosphorylation and
conformational changes in insulin receptor sub-
strate-1 downstream of the IGF-1R.
39
A third possible reason that may inﬂuence the
IGF-1 system is related to growth hormone (GH).
This important anabolic hormone has direct and
indirect actions on protein synthesis of different
tissues, including skeletal muscle.
40,41 Importantly,
the indirect effects of GH are mediated mainly
through the production of IGF-1.
42,43 Morselli
et al. found that the majority (73%) of ALS
patients have a GH deﬁciency, and thus this condi-
tion could induce a reduction of tissue IGF-1
synthesis.
44
Finally, we considered that the initial response
of the IGF-1 receptor to its ligand is related to an
autophosphorylation on speciﬁc tyrosine residues.
The intrinsic tyrosine kinase activity of IGF-1R
phosphorylates multiple substrates that determine
the activation of several downstream molecules,
such as the serine–threonine kinase Akt. Thus,
Leger et al. observed reduced active Akt in skeletal
muscle of ALS patients and G93A SOD1 transgenic
mice, which may be the ‘‘tip of the iceberg.’’
45 In
other words, the reduction of Akt coincides with
the decreased expression of IGF-1 and the
increased expression of IGF-1R that we observed.
According to morphological criteria and results
of histometrical analysis the degrees of denervation
were similar between sALS and PC patients. These
data support the idea that the augmented expres-
sion of IGF-1R in ALS skeletal muscles is not an
effect of denervation but could be a speciﬁc phe-
nomenon in sALS patients.
In this scenario it is also worth considering the
relevant role of BPs in the balance of effects
caused by the IGF-1 system components. IGF-BP3
is the most abundant circulating BP and exerts a
complex array of functions at the cellular level. Pri-
marily, IGF-BP3 inhibits IGF-1–mediated effects via
high-afﬁnity sequestration of the ligand, presum-
ably leading to prevention of IGF-1R autophospho-
rylation and signaling.
18 It has also been reported,
based on competitive ligand-binding studies, that
IGF-BP3 can interact with IGF-1R, causing inhibi-
tion of IGF-1 binding to its receptor.
46
FIGURE 5. WB analysis of IGF-1Rb expression in primary
adult skeletal muscle cell cultures from 2 sALS patients and
2 age-matched HCs (A control of C and B control of D).
Densitometric analysis is also shown. WB, Western blot; HC,
healthy control.
206 IGF System in Sporadic ALS Skeletal Muscle MUSCLE & NERVE February 2012However, the recombinant human (rh)IGF-1/
IGF-BP3 complex, which improves the safety and
efﬁcacy proﬁle of rhIGF-1 alone,
47 has an anabolic
potential demonstrated in catabolic conditions
such as burn injuries.
48 In an ad hoc animal study,
the IGF-1/IGF-BP3 complex, but not IGF-1 alone,
was able to support muscle protein synthesis in
rats during semi-starvation.
49 IGF-BP5 is considered
a stimulatory BP because it seems to counteract
the inhibitory actions of other BPs, such as IGF-
BP4, in systems such as bone
50 and cultured vascu-
lar smooth muscle cells.
51 It is noteworthy that, in
this study, we observed a reduced expression of
IGF-1 and IGF-BP3 and -BP5, which could suggest
a negative interference of muscle anabolism in
ALS patients, even when considering the
unchanged IGF-BP4 content in their muscle.
Previously, we demonstrated a high level of the
active fraction of IGF-1 (free IGF-1) in the cerebro-
spinal ﬂuid (CSF) of sALS patients without any
change in serum and CSF levels of total IGF-1.
52 In
the present study we found a distinctive expression
of IGF-1 and IGF-BP3 and -BP5 according to mus-
cle ﬁber types, with a higher expression level of
slow-twitch (ST) or type I ﬁbers compared with
fast-twitch (FT) or type II ﬁbers (checkboard pat-
tern). In light of this distribution, which was previ-
ously shown only in rat skeletal muscle ﬁbers for
the two BPs,
53 the different resistance to denerva-
tion by the two types of muscle ﬁbers should be
considered. Pun et al. showed that in two mouse
models of motoneuron disease (G93A SOD1 and
G85R SOD1), axons of fast-fatigable motoneurons
are affected synchronously, long before symptoms
appear.
54 Thus, fast-fatigue–resistant motoneuron
axons are affected at symptom onset, whereas
axons of slow motoneurons are resistant.
In conclusion, ALS is emerging as a ‘‘multisyste-
mic’’ disease in which structural, physiological, and
metabolic alterations in different tissues or cell
types (motoneurons, glia, and muscle ﬁbers) may
act synergistically to induce and/or exacerbate the
disease.
55,56 The cell interaction represents a func-
tional cross-talk between neuronal and non-neuro-
nal cells, whose derangement could make some
therapeutic strategies ineffective. Therefore,
although dysfunctions in the IGF-1 system empha-
size the potential therapeutic role of IGF-1 in sALS,
we should be aware that some disease-related tissue
abnormalities can interfere with the potential thera-
peutic properties of this neurotrophic factor.
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